| Cancer Cell International | |
| Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease | |
| Zonghong Shao1  Jia Song1  Huaquan Wang1  Guojin Wang1  Erbao Ruan1  Shan Gao1  Lijuan Li1  Yihao Wang1  Sijie Zhao1  Hui Liu1  Rong Fu1  | |
| [1] Department of Hematology, Tianjin Medical University General Hospital, 154 Anshao Street, Heping District 300052, Tianjin, PR China | |
| 关键词: Osterix; Runx2; Osteoblast; Myeloma bone disease; Chemokine cytokine ligand 3; | |
| Others : 1121611 DOI : 10.1186/s12935-014-0132-6 |
|
| received in 2014-09-18, accepted in 2014-11-17, 发布年份 2014 | |
PDF
|
|
【 摘 要 】
Background
Multiple myeloma is a hematologic malignancy characterized by the accumulation of monoclonal plasma cells in the bone marrow. A common manifestation of the disease is myeloma bone disease (MBD), which is caused by increased osteoclastic bone resorption and decreased bone formation. The chemokine cytokine ligand 3 (CCL3) is a pro-inflammatory protein and chemokine that stimulates osteoclasts in MBD. However, little is known about the effect of CCL3 on osteoblasts (OB).
Methods
The OBs are induced from patients with MBD and healthy donors, cultured in vitro, and identified by histochemistry. The effects of CCL3 and CCL3 antibody on the OBs in vitro are observed. The CCL3 receptor (CCR1), osteocalcin (OCN), runt-related transcription factor 2 (Runx2), and osterix (Osx) are detected using flow cytometry, enzyme-linked immunosorbent assay, and real-time PCR.
Results
Proliferation and osteogenic potential of the OB in patients with MBD are suppressed. Moreover, the CCR1 expression is significantly higher in patients with MBD than in normal controls. The OCN level, quantity of calcium nodules, and Runx2 and Osx levels decrease after CCL3 stimulation, which indicates that CCL3 inhibits OB function. Furthermore, CCL3 antibody partially restores OB activity through the upregulation of the OCN, Runx2, and Osx.
Conclusions
CCL3 contributes to the OB/OC imbalance by inhibiting OB differentiation and function in MBD.
【 授权许可】
2014 Fu et al.; licensee BioMed Central Ltd.
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 20150212030639232.pdf | 2033KB | ||
| Figure 4. | 110KB | Image | |
| Figure 3. | 50KB | Image | |
| Figure 2. | 126KB | Image | |
| Figure 1. | 96KB | Image |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
【 参考文献 】
- [1]Taube T, Beneton MNC, McCloskey EV, Rogers S, Greaves M, Kanis JA: Abnormal bone remodeling in patients with myelomatosis and normal biochemical indices of bone resorption[J]. Eur J Haematol 1992, 49(4):192-198.
- [2]Roodman GD, Choi SJ: MIP-1 Alpha and Myeloma Bone Disease. In The Biology of Skeletal Metastases. In Cancer Treatment and Research Volume 118. 2nd edition. Edited by Keller ET, Leland WK C. Springer, US; 2004:83-100.
- [3]Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A: Serum levels of macrophage inflammatory protein - 1 alpha (MIP - 1α) correlate with the extent of bone disease and survival in patients with multiple myeloma[J]. Br J Haematol 2003, 123(1):106-109.
- [4]Hata H: Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1α) in human multiple myeloma[J]. Leuk Lymphoma 2005, 46(7):967-972.
- [5]Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dorken B, Bargou RC: PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells[J]. Leukemia 2004, 18(11):1883-1890.
- [6]Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY: Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells[J]. Blood 2003, 101(9):3568-3573.
- [7]Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O: Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease[J]. Biochem Biophys Res Commun 2005, 338(2):687-693.
- [8]Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD: Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand[J]. Blood 2001, 97(11):3349-3353.
- [9]Silvestris F, Cafforio P, De Matteo M, Calvani N, Frassanito MA, Dammacco F: Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells[J]. Clin Cancer Res 2008, 14(19):6081-6091.
- [10]Silvestris F, Lombardi L, De Matteo M, Bruno A, Dammacco F: Myeloma bone disease: pathogenetic mechanisms and clinical assessment[J]. Leuk Res 2007, 31(2):129-138.
- [11]Roodman GD: Pathogenesis of myeloma bone disease[J]. Blood Cell Mol Dis 2004, 32(2):290-292.
- [12]Fu R, Gao S, Peng F, Li J, Liu H, Wang H, Xing L, Shao Z: Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma. Cancer Cell International 2014, 14:62. doi:10.1186/1475-2867-14-62 BioMed Central Full Text
- [13]Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr: Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma[J]. Bone 2008, 42(4):669-680.
- [14]Wang YH, Liu Y, Buhl K, Rowe DW: Comparison of the Action of Transient and Continuous PTH on Primary Osteoblast Cultures Expressing Differentiation Stage‐Specific GFP[J]. J Bone Miner Res 2005, 20(1):5-14.
- [15]Green S, Chambon P: Carcinogenesis: a superfamily of potentially oncogenic hormone receptors[J]. Nature 1986, 324:615-617.
- [16]Barnes MJ: Function of ascorbic acid in collagen metabolism[J]. Ann N Y Acad Sci 1975, 258(1):264-277.
- [17]Bellows CG, Aubin JE, Heersche JN, Antosz ME: Mineralized bone nodules formedin vitro from enzymatically released rat calvaria cell populations[J]. Calcif Tissue Int 1986, 38(3):143-154.
- [18]Anderson RE, Kemp JW, Jee WS, Woodbury DM: Ion-transporting ATPases and matrix mineralization in cultured osteoblastlike cells[J]. In Vitro 1984, 20(11):837-846.
- [19]Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C: Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease[J]. J Clin Oncol 1989, 7(12):1909-1914.
- [20]Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F: Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease[J]. Br J Haematol 2003, 122(1):39-52.
- [21]Fuller K, Owens JM, Chambers TJ: Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts[J]. J Immunol 1995, 154(11):6065-6072.
- [22]Kukita T, Nomiyama H, Ohmoto Y, Kukita A, Shuto T, Hotokebuchi T, Sugioka Y, Miura R, Iijima T: Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment[J]. Laboratory Invest 1997, 76(3):399-406.
- [23]Tsubaki M, Kato C, Manno M, Ogaki M, Satou T, Itoh T, Kusunoki T, Tanimori Y, Fujiwara K, Matsuoka H, Nishida S: Macrophage inflammatory protein-1α (MIP-1α) enhances a receptor activator of nuclear factor κB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways[J]. Mol Cell Biochem 2007, 304(1–2):53-60.
- [24]Olsen BR, Reginato AM, Wang W: Bone development[J]. Annu Rev Cell Dev Biol 2000, 16(1):191-220.
- [25]Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P, Hideshima T, Santo L, Cirstea D, Scadden DT, Anderson KC, Raje N: A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function[J]. Leukemia 2011, 25(7):1174-1181.
- [26]Komori T: Regulation of bone development and maintenance by Runx2[J]. Front Biosci: a journal and virtual library 2007, 13:898-903.
- [27]Nishio Y, Dong Y, Paris M, O’Keefe RJ, Schwarz EM, Drissi H: Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene[J]. Gene 2006, 372:62-70.
- [28]Gao Y, Jheon A, Nourkeyhani H, Kobayashi H, Ganss B: Molecular cloning, structure, expression, and chromosomal localization of the human Osterix (SP7) gene[J]. Gene 2004, 341:101-110.
- [29]Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C: Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes[J]. Dev Cell 2005, 8(5):727-738.
- [30]Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation[J]. Dev Cell 2005, 8(5):751-764.
- [31]Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB: Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression[J]. J Biol Chem 2005, 280(39):33132-33140.
PDF